Bonito Biosciences and DaltonTx announced a collaboration to develop precision delivery systems for oligotherapeutics, a class of drugs including antisense oligonucleotides and siRNAs. The partnership aims to overcome one of the field's biggest hurdles: delivering these molecules to specific tissues and cell types that have remained inaccessible.
The companies plan to combine closed-loop functional screening with AI-driven design to accelerate discovery. This approach allows iterative testing of delivery vehicles in relevant biological models, with machine learning guiding the optimization of candidates for better targeting and efficacy.
No specific clinical trial phases, patient populations, or efficacy rates were disclosed. The collaboration is described as a research-stage effort focused on platform development rather than a specific therapeutic candidate. Financial terms and timeline were not provided.
For Bonito and DaltonTx, this partnership represents a bet on AI-powered drug delivery as a key enabler for the oligotherapeutics market, which has grown with recent approvals but remains limited by delivery challenges. Both companies are private, and no stock movements or funding rounds were disclosed.
Industry observers note that while AI-driven delivery platforms offer promise, many similar efforts have yet to produce validated in vivo results. The lack of disclosed preclinical data makes it difficult to assess the platform's potential impact on patient access or clinical outcomes.